FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
|Articles|August 9, 2021
FDA Approves New Treatment for Pompe Disease
Author(s)BioPharm International Editors
FDA has approved the intravenous medication Nexviazyme for treatment of Pompe Disease.
Advertisement
On August 6th, 2021, FDA announced that they had approved Nexviazyme for intravenous infusion to treat patients one year or older with Pompe Disease. It has been granted Fast Track, Priority Review, and Breakthrough Therapy designations, in addition to an orphan drug designation.
Pompe Disease is a condition that causes excess build-up of glycogen (which is typically broken down into glucose and released into the bloodstream to provide energy to cells) in skeletal and heart muscles, according to the agency. This causes muscle weakness and can lead to premature death from respiratory or heart failure.
Nexviazyme is an intravenous drug designed to reduce glycogen levels. A study was done wherein 100 patients with Pompe’s Disease were randomly given either Nexviazyme or another FDA approved enzyme-replacement therapy. The results found similar levels of efficacy between Nexviazyme and the approved therapy.
“Today’s approval brings patients with Pompe disease another enzyme replacement therapy option for this rare disease,” said Janet Maynard, deputy director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, in a press release. “The FDA will continue to work with stakeholders to advance the development of additional new, effective, and safe therapies for rare diseases, including Pompe disease.”
Source:
Advertisement
Related to this article
FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5